Figure 1.

VSV-NDV reduces the tumor mass and mediates the expression of cytokines in murine melanoma. (A) The experimental set-up of the mechanistic endpoint experiment. C57BL6/J mice were implanted with B16OVA cells subcutaneously on contralateral flanks. Seven days later, the mice were randomly distributed into treatment groups (N = 6–8) and injected intratumorally with VSV-NDV (VN) at a dose of 1 × 10⁷ TCID50 or PBS in an equal volume of 50 µL on day 0, 3, 6. Tumors were collected on days 2 and 10 post-treatment start. Created in BioRender. Altomonte, J. (2024) https://BioRender.com/p46u790. (B) Tumor weight was measured on day 10. (C) Quantitative real-time RT-PCR was performed to measure intratumoral mRNA expression on day 2 (IL-15, IFN-$\gamma$, IFN-α, IFN-β, and CXCL10) or day 10 (T-bet). Relative gene expression was quantified by normalization to GAPDH using the 2^−ΔΔCt method. Data points indicate values of individual replicates (and group means are presented as bars); * indicates p ˂ 0.05, and ** indicates p ˂ 0.01).